Oxylipin profiling for clinical research: Current status and future perspectives
Résumé
Oxylipins are potent lipid mediators with increasing interest in clinical research. They are usually measured in
systemic circulation and can provide a wealth of information regarding key biological processes such as
inflammation, vascular tone, or blood coagulation. Although procedures still require harmonization to generate
comparable oxylipin datasets, performing comprehensive profiling of circulating oxylipins in large studies is
feasible and no longer restricted by technical barriers. However, it is essential to improve and facilitate the
biological interpretation of complex oxylipin profiles to truly leverage their potential in clinical research. This
requires regular updating of our knowledge about the metabolism and the mode of action of oxylipins, and
consideration of all factors that may influence circulating oxylipin profiles independently of the studied disease
or condition. This review aims to provide the readers with updated and necessary information regarding oxylipin
metabolism, their different forms in systemic circulation, the current limitations in deducing oxylipin cellular
effects from in vitro bioactivity studies, the biological and technical confounding factors needed to consider for a
proper interpretation of oxylipin profiles.
Mots clés
Lipid mediators Epilipids Lipidomics Oxylipins Eicosanoids Clinical translation
Lipid mediators Epilipids Lipidomics Oxylipins Eicosanoids Clinical AA
arachidonic acid ALA
alpha-linolenic acid BLT
leukotriene B4 receptor CE
cholesteryl ester COX
cyclooxygenase CYP
cytochrome P450 monooxygenase DHA
docosahexaenoic acid EP
prostaglandin E2 receptor EpOME
epoxyoctadecamonoenoic acid EPA
eicosapentaenoic acid HDL
high-density lipoprotein HEPE
hydroxyeicosapentaenoic acid HETE
hydroxyeicosatetraenoic acid HODE
hydroxyoctadecadienoic acid LA
linoleic acid LLE
liquid-liquid extraction LOX
lipoxygenase lysoPL
lysophospholipid LT
leukotriene LX
lipoxin MS
mass spectrometry NSAIDs
non-steroidal-anti-inflammatory-drugs Oxo-ODE
oxooctadecadienoic acid PG
prostaglandin PGI
prostacyclin PL
phospholipid PLA 2
phospholipase
arachidonic acid
ALA
alpha-linolenic acid
BLT
leukotriene B4 receptor
CE
cholesteryl ester
COX
cyclooxygenase
CYP
cytochrome P450 monooxygenase
DHA
docosahexaenoic acid
EP
prostaglandin E2 receptor
EpOME
epoxyoctadecamonoenoic acid
EPA
eicosapentaenoic acid
HDL
high-density lipoprotein
HEPE
hydroxyeicosapentaenoic acid
HETE
hydroxyeicosatetraenoic acid
HODE
hydroxyoctadecadienoic acid
LA
linoleic acid
LLE
liquid-liquid extraction
LOX
lipoxygenase
lysoPL
lysophospholipid
LT
leukotriene
LX
lipoxin
MS
mass spectrometry
NSAIDs
non-steroidal-anti-inflammatory-drugs
Oxo-ODE
oxooctadecadienoic acid
PG
prostaglandin
PGI
prostacyclin
PL
phospholipid
PLA 2
Domaines
Médecine humaine et pathologie| Origine | Fichiers éditeurs autorisés sur une archive ouverte |
|---|---|
| Licence |
